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CObjectives: Generic health status measures such as the short form
health survey (SF-36) and EuroQol-5D (EQ-5D) are increasingly being used
to inform health policy. They are claimed to be applicable across disease
areas and have started to be used within mental health research. This
review aims to assess the construct validity and responsiveness of four
generic health status measures in schizophrenia, including the prefer-
ence-based SF-6D and EQ-5D. Method: A systematic review of the litera-
ure was undertaken. Ten databases were searched from inception to
ugust 2009 and reference lists scrutinized to identify relevant studies.
tudies were appraised and data extracted. A narrative synthesis was
erformed of the evidence on construct validity including known groups
alidity (detecting a difference in health-related quality of life (HRQL)
cores between two different groups such as samples from the general
opulation and people with schizophrenia), convergent validity (strength
f association between generic HRQL and other measures (e.g., symptom
r functional), and responsiveness. Responsivenesswas considered by: 1)
ifferences in generic HRQLmeasure scores in responders/non-respond-
rs and 2) correlation between changes on generic HRQL measures and
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Changes in specific measures obtained from patients and clinicians.
esults: Thirty-three studies were identified that provided data on the
alidity and/or responsiveness of the instruments. Most of the evidence
oncerns the SF-36 and EQ-5D, and for these instruments there was evi-
ence for known group validity. The evidence for convergent validity and
esponsivenesswasmixed,with studies presenting contradictory results.
onclusion: Although the evidencebase is limited in anumber of impor-
ant respects, includingproblemswith themeasuresused todevelop con-
tructs in the validation studies, it is sufficient to raise doubts about the
se of generic measures of health like the EQ-5D and SF-36 in patients
ith schizophrenia.
eywords: EQ-5D, generic health status measures, health-related qual-
ty of life, preference-based measures, quality of life, schizophrenia,
F-36, SF-12, SF-6D.
opyright © 2011, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc. Open access under -C BY license.Introduction
Generic health status measures such as short form health survey
SF-36) andEuroQol-5D (EQ-5D) are increasingly beingused to inform
ealth policy. The last decade has seen the increased use of eco-
omic evaluation, particularly the use of cost-effectiveness analyses
y agencies such as National Institute for Health and Clinical Excel-
ence (NICE) to inform resource allocation decisions [1], where inter-
ventions are assessed in terms of their cost per quality adjusted life
year (QALY). The QALY provides a way of measuring the benefits of
health care interventions, including improvements in health-related
quality of life (HRQL) usually measured using a generic measure like
EQ-5D. There has been, however, only a limited use of generic mea-
sures of health in mental health [2].
It is claimed that the EQ- 5D and other generic preference-based
measures suchas theSF-6D [3] are applicable to all interventions and
patient groups. This claim has support in many physical conditions
where these instruments have managed to pass psychometric tests
of reliability andvalidity [4]. For other conditions the claimhasnot be
* Address correspondence to:Diana Papaioannou, Research Fellow
Court, 30 Regent Street, Sheffield, S1 4DA UK.
E-mail: d.papaioannou@sheffield.ac.uk.
1098-3015Copyright © 2011, International Society for Pharmacoec
pen access under CC BY license.substantiated, such as in relation to visual impairment in macular
degeneration [5] and hearing loss [6]. Doubts have also been raised
bout the appropriateness of generic measures in mental health [7].
ne solution would be to use disease-specific HRQL measures, for
xample there have been attempts to derive preference-basedmea-
ures from the positive and negative syndrome scale (PANSS) and
linical outcomes in routine evaluation – outcome measure (CORE-
M) [8,9] in mental health. There are concerns, however, about the
omparability of such disease-specific scales and in theUnited King-
om, health technology assessment submissions to NICE are ex-
ected to follow the details outlined in the reference case analysis
escribed by the NICE methods guide. This clearly stipulates that
hereverpossibleandappropriate, theEQ-5D is the favoredmeasure
or generating utility values [1], thus allowing a common metric to
ssess health care interventions. Alternativemeasuresmay be used
here the EQ-5D has been empirically demonstrated to be inappro-
riate in terms of their validity and responsiveness to change and
everal studies have been undertaken providing such evidence.
Inorder toprovidea reasonedassessmentof theappropriatenessof
enericHRQLmeasures inpatientswithschizophrenia,wehaveunder-
ool of Health and Related Research, University of Sheffield, Regent
ics and Outcomes Research (ISPOR). Published by Elsevier Inc.
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908 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 0 7 – 9 2 0taken a systematic review to investigate the construct validity and re-
sponsiveness of two generic HRQL profile measures (SF-36, SF-12) and
twopreference-basedHRQLmeasures (SF-6D, EQ-5D) in schizophrenia.
Methods
Measures being evaluated
The SF-36 is a generic health status profile measure consisting of
eight dimensions of general health (GH); bodily pain (BP); physical
functioning (PF); role-physical (RP), mental health (MH); vitality
(V); social functioning (SF), and role-emotional (RE). These eight
dimensions also can be used to generate a physical and mental
health summary scores [10]. The SF-12 [11] is a shortened version
of the SF-36, containing 12 of the SF-36 items, and also produces
two weighted summary scores (PCS and MCS).
TheEQ-5Dvaluationquestionnaire comprises afive-dimensional
questionnaire and an EQ-5D visual analogue scale (VAS). Respon-
dents are asked to provide a position on the EQ-5D health state
classification and to report their level of problems (no problems,
some/moderate problems or severe/extreme problem) on the
questionnaire, which includes mobility, self-care, usual activities,
pain, and anxiety/depression. Responses can be converted into one
of 243 different health state descriptions (ranging from no problems
on any of the dimensions [11111] to severe problems on all five di-
mensions [33333]) and each one has its own preference-based score.
Preference-based scores are determined by eliciting preferences: es-
tablishing which health states are preferred from a population sam-
ple. In order to do so, a method such as time trade off is used and
involves asking participants to consider the relative amounts of time
(for example, number of life-years) they would be willing to sacrifice
to avoid a certain poorer health state [12]. Utility values from the UK
EQ-5D can range from –0.59 to 1, where negative values are felt to be
worse thandeathandavalueof 1 indicatesperfecthealth.TheEQ-5D
VAS reports on the respondent’s self-rated valuation of his or her
health stated; thus, it is basedon thepreferencesof thepatient, but is
not preference based and not normally used to generate QALYs.
The SF-6D is a preference-based measure of health that can be
generated from items of the SF-36 or SF-12 [3,13]. The SF-6D has a
classification that describes health on six multilevel dimensions of
physical functioning, role limitations, social functioning, pain, mental
health,andvitality.Therearealgorithmsforscoringeachstatebasedon
values obtained from general population surveys using standard gam-
ble (respondentsmakeaseriesof choiceswhichallowestimationof the
strength of preferences regarding a health state). Health state utility
values range from 0.29 to 1.0. These health state utility values can be
used to calculate QALYs for cost-effectiveness analysis.
Inclusion and exclusion criteria
Studies were eligible for inclusion if they contained HRQL data using
one or more of the following instruments: SF-36, SF-12, SF-6D, or
EQ-5D within the specified population: adults (18 years old) with
schizophrenia or schizophrenia-related disorders (e.g., schizo-
phreniformdisorder or schizoaffective disorder). HRQLdata could be
from descriptive systems (i.e., their items and dimensions), health
state utility values generated by the EQ-5D or SF-6D, or the EQ-5D
VAS. Studies with the primary focus on individuals with alcohol
and/or drug dependency with comorbid schizophrenia or schizo-
phrenia-related disorder were excluded. The outcomes had to in-
clude data that allowed measurement of the construct validity (i.e.,
known groups or convergent) or the responsiveness of the HRQL in-
strument(s). Responsiveness data had to be in the form of effect
sizes, standardized response means (SRMs), or correlation with
change scores on symptom measures. Studies that only provided
data on other psychometric properties such as reliability, face valid-
ity, and content validity were not included.Identification of studies
As part of a wider review of HRQL measures in mental health
funded by the Medical Research Council (MRC), this review fo-
cused on the construct validity and responsiveness of the four
generic HRQLmeasureswithin schizophrenia. Other reviewswere
carried out, each focusing on onemental health condition, as part
of the wider review. A literature search was performed to identify
relevant research for all mental health conditions being investi-
gated within the wider review using database thesaurus and free
text terms. Two sets of search termswere combined: terms for each
of the four HRQL measures AND terms for the each mental health
condition (search strategies are available from authors). Ten data-
bases were searched for published research from inception: Co-
chrane Database of Systematic Reviews, Cochrane Central Register
of Controlled Trials, NHS Economics and Evaluations Database,
Health Technology Database, Database of Abstracts of Reviews of
Effects, MEDLINE, PreMEDLINE, CINAHL, EMBASE, and Web of Sci-
ence. Searcheswere limited to English language only, but not by date
restriction. All searches were conducted in August 2009. The refer-
ence lists of relevant studies were searched for further articles.
Citations identified by the searching process were screened by
one reviewer (DP)using the inclusioncriteria. The full texts of articles
were retrieved for any titles or abstracts that appeared to satisfy the
inclusion criteria, or for which inclusion or exclusion could not be
definitely determined. The same inclusion and exclusion criteriawere
used toassess full articles andanyqueriesover inclusionwere resolved
by discussion and consensus between two reviewers (DP/JB).
Data extraction
Data from all included trials were extracted using a form designed
specifically for this review, and piloted on one paper [6]. Data ex-
tracted included: country of publication, type of disorder, study
sample characteristics (numbers, age, gender), other measures
used,mean scores onHRQLmeasures, type andmethod of validity
assessment, type and method of responsiveness assessment, and
validity and responsiveness data. Extractions were performed by
one reviewer (DP). Where duplicate publications reported on sim-
ilar data, the most complete and recent data were extracted.
Quality assessment
There isnoformalmethodforassessingthequalityof thesestudies (i.e.,
there are no quality assessment checklists). Themethods described by
Fitzsimmonsetal. [14]wereusedtoevaluateHRQLdata intheirsystem-
tic reviewon theuse andvalidationofHRQL instrumentswithin older
ancer patients. This included whether tests of statistical significance
ere applied, differences between treatment groups were reported
where applicable, e.g., in known groups validity), clinical significance
iscussed, and missing data were documented. We also report on re-
ponse and completion rateswhere these are provided.
Evidence synthesis and meta-analysis
Due to the large degree of heterogeneity between studies (includ-
ing types of study designs, HRQL instruments, population charac-
teristics and methods of determining construct validity, and re-
sponsiveness), it was not appropriate to perform meta-analysis.
Analysis was by narrative synthesis and data were tabulated. All
analyses were performed based on the HRQL instrument, with
data analysis grouped by type of validity (convergent/discriminant
or known groups) or responsiveness measured.
Defining validity and responsiveness
Validity
Construct validity is defined as the extent to which an instrument
measures the construct it is designed tomeasure and in the settings
e
c
t
p
e
909V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 0 7 – 9 2 0it is designed for [15,16]. Construct validity can be measured by
known or extreme groups where in theory, in two groups who differ
in a trait or behavior, one group is expected to score significantly
higher or lower compared with the other group [16]. Care must be
taken to ensure that the groups are hypothesized to have different
scores and for preference-basedmeasures caremust be taken to en-
sure that patients and the general public would have clear prefer-
ences for one over the other [17]. Convergent validity assesses the
relationship of the instrument of interest to other measures of the
sameconstruct towhich it shouldbe related [16]. Convergent validity
is the correlation between two measures that in theory are associ-
ated. Again, the instrument being used to test convergence of EQ-5D
and SF-6D must be a good indicator of the trait or behavior, such as
another preference-basedmeasuremay be hypothesized to be likely
to have a strong relationship to preferences. The strength of correla-
tion between the two instruments was calculated using statistical
tests (Pearson’sproductmomentcorrelationorSpearman’s rankcor-
relation). We have used the following categories for evidence of cor-
relation: 0.6, very strong; 0.5 to 0.6, strong; 0.5 to  0.3, mod-
rate; and 0.3, weak. Statistical significance was also attached to
orrelations (P 0.05).
Responsiveness
Walters [15] defined responsiveness as the extent to which an
instrument can detect a clinically significant or practically impor-
tant change over time. Any changemust be perceptible and impor-
ant to patients, and something that would be valued by the general
ublic. Responsiveness can be measured in a number of ways by
ffect size statistics [15] standardized in different ways, such as di-
Fig. 1 – Flow diagramviding through by the SD at baseline or SD of the change in scoresover time (i.e., standardized response means). Within this review,
Cohen’s [18] categories formagnitudeof effect sizewereused: 0.80,
large;0.80 and 0.50, moderate; and 0.30 to0.50, small.
The application of these psychometric criteria to preference-
based measures requires some adaptation [17].The purpose of
EQ-5D or SF-6D is to identify all differences or changes in health
that are important to patients and valued by the general public. An
item of the EQ-5D, for example, may fail to pick up small differ-
ences in one condition-specific dimension or miss another health
dimension entirely, but if these are not important to patients and
not valued by the general population, then it is not a weakness of
the instrument. Equally, the EQ-5D may fail to reflect clinical dif-
ferences, but these may not be important to patients. Thus, the
tests of construct and convergent validity and responsiveness
need to be applied with care.
Results
Study characteristics
The search for studies for the wider review retrieved 4115 unique
citations (Fig. 1). Of these, 3849 were excluded at the title and
abstract stage and 266 full articles were examined. Another 12
studies were identified through reference list checking. Thirty-
three studies were identified that provided data on the validity
and/or responsiveness of the EQ-5D, SF-36, SF-12, or SF-6D (Tables
1–3 and Appendix found at doi:10.1016/j.jval.2011.04.006) within
individuals diagnosed with schizophrenia, schizophreniform dis-
tudy identification.of sorder, or schizoaffective disorder. Six studies were undertaken
Table 1 – EQ-5D validity and responsiveness.
Study Population characteristics Properties measured Source and types of measures
used to test convergent validity
and/or responsiveness
Details of validity or
responsiveness
Auquier (2003 ) [35] France DSM-IV schizophrenia Inpatients
and outpatients (numbers not
reported). N207 (141 males
and 66 females).Mean age,
37.3 (SD, 10.9) (range 18–70
years).
Convergent validity Patient–completed
i) Quality of life-disease specific
(S-QOL)
Correlations with EQ-5D descriptive
system health states and SQoL
dimensions ranged from
0.06 (SQoL family relationships)
to 0.56 (SQoL self-esteem).
Generally moderate correlations,
overall correlation with S-QOL
index was moderate and
significant: 0.48, P  0.05
Badia (1999) [49] Country not
reported
Schizophrenia (classification not
reported). Napprox
2949 (n2128 olanzapine;
n821 risperiodone or
haloperidol; small numbers on
other antipsychotics). No age,
gender or inpatient/outpatient
status reported.
Responsiveness No measures reported EQ-VAS and EQ-5D index recorded
large effect sizes (0.98 and 1.13,
respectively) for olanzapine-
treated patients pre- and post-
treatment and moderate to large
effect sizes for other
antipsychotics (0.58 to 0.75 for
VAS and 0.78 to 0.96 for index).
Barton (2009) [41] UK Non-affective psychosis
diagnosis (criteria not
specified). Includes:
schizophrenia, schizoaffective
disorder, bipolar disorder, and
psychotic depression.
Participants had to screen
positive for psychotic
symptoms and in relative
remission (4 on PANSS).
N77 (55 males, 22 females).
Mean age, 28.9 years; range
18–52.50/77 had a diagnosis of
non-affective psychosis.
Inpatient/outpatient status not
reported.
Known groups validity. Convergent
validity. Responsiveness
Clinician-completed
i)Symptoms PANSS
ii)Functioning GAF, SOFAS
iii)Quality of life-disease specific
QLS (interviewer administered)
Patient-completed
i) Symptoms BAI, BDI, BHS
EQ-5D Index scores showed at least
a minimally important clinical
difference (MID) (defined as
0.03) between those with
milder and more severe scores
on symptom and functioning
measures. Correlations between
the EQ-5D index and three
symptom measures (BAI, BDI,
BHS) were moderate to very
strong (0.360–0.656). A significant
but weak correlation was found
with a measure the GAF(0.263).
Non-significant and weak
correlations were seen with the
PANSS, QLS and SOFAS. Mean
EQ-5D scores were higher for
those who improved than those
who did on improve on 6 of 7
symptom or functioning
measures. The difference in
means between improvers and
non-improvers was equal to or
greater than the MID (0.03).
(continued on next page)
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Table 1 (continued)
Study Population characteristics Properties measured Source and types of measures
used to test convergent validity
and/or responsiveness
Details of validity or
responsiveness
Konig (2007) [30] Germany ICD-10: Schizophrenia,
schizotypal or delusional
disorders. 49.4% outpatient;
41.6 % inpatient; 9.0% day
clinic. N166 (97 males, 69
females). Mean age, 40.5 (SD,
11.1); range 21–80 years.
Convergent validity Clinician-completed
i) Symptoms PANSS, SCL-90R &
CGI-S
ii) Functional GAF, GARF, SOFAS &
HoNOS
Patient-completed
i) Quality of life-generic TTO direct
utility & WHOQOL-BREF
Effect sizes (calculated using the
mean values of symptom and
functioning measures between
individuals who answered “yes”
or “no” for each EQ-5D
dimensions) were mostly
moderate to large for symptom
measures ( 0.37–1.29) and
functioning measures (0.24–1.4).
Effect sizes for the for the pain/
discomfort dimension were
smaller. Moderate correlations
recorded between EQ-5D VAS
and index and symptom
measures (0.34–0.73), functioning
measures (0.20–0.65), and generic
quality of life measures
(0.47–0.57).
Konig (2009) [31] Germany ICD-10: Schizophrenia,
schizotypal or delusional
disorders.51.7% outpatient;
38.5% inpatient, and 9.8 day
clinic. N143 (83 males and 60
females). Mean age, 40.4 (SD,
11.6).
Convergent validity Clinician-completed
i) Symptoms PANSS, SCL-90R,
CGI-S, and BRAMES
ii) Functional GAF, GARF, SOFAS,
and HoNOS
Patient-completed
ii) Quality of life-generic TTO direct
utility & WHO-QOL-BREF
Correlation with the TTO direct
elicitation of utility values and
the EQ-5D VAS and EQ-5D index
(UK and German) were weak in
correlation (0.25). However, the
TTO method did not correlate
well with a number of
theoretically related measures.
McCrone (2009) [20] The Netherlands,
Germany, UK, and Italy
SCAN interview diagnosed
schizophrenia (classification
scheme not specified).“Chronic
high disability sample” based
on number of years on
medication, number of
psychiatric inpatient days last
year, and GAF score.
N409 (245 males and 164
females). Mean age, 41.5 (SD,
11.5); no range reported.
Convergent validity.
Responsiveness
Clinician-completed
i) Symptoms BPRS
Moderate correlation (0.343) with
EQ-5D index and a symptom
measure (BPRS) at baseline. Weak
correlation (0.29) with changes in
symptom measure after
treatment. Where improvement
on BPRS was at least 25%, EQ-5D
SRM was small in size (0.39).
Where deterioration on BPRS was
at least 25% or improvement on
BPRS 25%, EQ-5DSRMs were
very small (0.17 and 0.05
respectively).
Prieto (2004) [38] Spain ICD-10 Schizophrenia.
N2657 (1691 males and 966
females). Not stated if
inpatient or outpatient
N2128 on olanzapine; n417
on risperidone; n112 on
haloperidol. Mean age,
35.32 (SD, 11.57); range not
reported.
Convergent validity Clinician-completed
i) Symptom CGI-S
ii) FunctionalGAF
EQ-5D index and EQ-5D VAS both
demonstrated moderate to
strong association with one
symptom (CGI-S) and one
functional measure (GAF), range
0.34–0.54, P  0.001).
(continued on next page)
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Table 1 (continued)
Study Population characteristics Properties measured Source and types of measures
used to test convergent validity
and/or responsiveness
Details of validity or
responsiveness
Scalone (2008) [47] Italy N 637 (n551with
schizophrenia n86 with
schizophreniform disorder ).
414 males and 223 females;
18–40 years old (no mean age
reported). Inpatient/outpatient
status not reported.
Convergent validity Clinician-completed
i) Symptom PANSS, CGI-S
ii) Functional GAF
Weak to moderate correlations
between QOL scores (EQ-5D and
SF-36) and symptom measures
(PANSS and CGI-S) ranging from
0.189–0.393.
van de Willige (2005) [40] The
Netherlands
DSM-IV schizophrenia (described
as chronic sample). Auditory
hallucinations for  2 years
after adequate treatment. Use
of at least 2 antipsychotic
drugs. Inpatients and
outpatients-numbers not
reported. N76 (42 males and
34 females). Mean age, 36
years (SD, 11.2).
Responsiveness Clinician-completed
i) Symptom PANSS, AHRS
ii) Functional GSDS
iii) Quality of life-generic WHOQOL-
BREF
Differences in EQ-5D descriptive
system scores between baseline
and follow-up were statistically
significant for the daily
functioning domain (Z1.79, P 
0.05  0.10) and
anxiety/depression domain
(Z3.53, P  0.001). Moderate
correlations between changes on
EQ-5D VAS and changes in
PANSS (total and subscales)
(0.34–0.47, P  0.01 and P 
0.0005). Correlations between
changes on EQ-5D index and
changes in PANSS existed only
on PANSS positive symptoms
subscale (0.53, P  0.001).
Moderate to strong correlations
with 3 of 4 AHRS subscales and
the EQ-5D VA (0.46–0.50, P 
0.001). The EQ-5D index was only
correlated with one AHRS
subscale and this was weak
(distress, 0.25, P  0.01).
Moderate correlations with social
function (GSDS) on both the EQ-
5D VAS (0.27–0.46, P ranges 
0.01 and  0.001) and EQ-5D
index (0.29–0.39, P ranges  0.05
and  0.005). WHOQoL-Bref
dimensions correlated for the
most part moderately to strongly
with the EQ-5D VAS (0.27–0.60)
and EQ-5D index (0.25–0.58).
Note: other measures used in the study, but not used to test convergent validity or responsiveness, are not listed.
AHRS, auditory hallucinations rating scale; BAI, Beck anxiety inventory; BDI, Beck depression inventory; BHS, Beck hopelessness scale; BPRS, brief psychiatry rating scale; BRAMES, Bech–Rafaelsen
melancholia scale; CDSS Calgary depression scale for schizophrenia; CGI-S, clinical global impression-severity; EQ-5D, EuroQol-5D; ESRS, extrapyramidal symptom rating scale; GAF, global
assessment of functioning; GARF, global assessment of relational functioning scale; GSDSGroningen social disabilities schedule; HoNOS, health of the nation outcome scales; PANSS, positive and
negative syndrome scale; QLS  quality of life scale; QoLI, quality of life inventory; SCL-90R, symptom checklist-90-R; SF-36, short form health survey; SOFAS, social and occupational functioning
assessment scale; S-QOL, schizophrenia quality of life questionnaire; TTO, time trade off; VAS, visual analogue scale; WHO-QOL-BREFWHO quality of life-BREF.
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913V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 0 7 – 9 2 0internationally acrossmore than one country [8,19–23]; six studies
were undertaken in the USA [24–29]; three in Germany [30–32];
wo in Ethiopia [33,34]; two in France [35,36]; two in Spain [37,38];
two in the Netherlands [39,40]; and two in the United Kingdom
41,42]. The remaining six studies took place in Australia [43], Can-
ada [44], Denmark [45], Hong Kong [46], Italy [47], and Poland [48].
Two studies did not report the country in which the study was
undertaken [49,50].
The number of participants in the studies with schizophrenia or
related conditions ranged from15 to 2657. Participants includedboth
genders and the proportions are reported in Tables 1, 2, and Appen-
dix found at doi:10.1016/j.jval.2011.04.006. The mean age of partici-
pants with a schizophrenia spectrum disorder, reported in 24 of the
33 studies, ranged between 20.3 and 57.9 years. Three studies pro-
vided an age range of participants, but not amean age [19,29,39]. Six
studies did not provide information on age [21,33,37,43,44,49].
All studies obtained HRQL information from patients: seven
studies compared patient HRQL values with published general
population “normative” values [22,23,25,28,33,34,45]; three com-
pared HRQL values with normal comparison participants that
were recruited to the study [24,29,32]; and two used “norms” from
healthy participants who had taken part in large surveys [43,46].
Quality of included studies
Quality assessment of the studies was restricted to items relating
to the quality of HRQL reporting and methods used in HRQL data
analysis as previously described (Table 4). All but four studies re-
ported tests for statistical significance of the properties measured
[33,43,45,49]. Twelve of the 20 studies where it was applicable re-
ported that tests were undertaken for difference between groups
(e.g., known groups validity, responsiveness). Nine of the 33 stud-
ies considered what constituted a clinically significant difference
in HRQL scores (Table 4), either by providing a predefined value or
discussing whether the results were clinically meaningful. How-
ever, there was no discussion or inclusion of clinical significance
defined in terms of patient perception; thus, from the perspective
of preference-based measures, the lack of patient preference un-
dermines the concept of clinical significance. Only three studies
fully reported missing HRQL data and four studies partly reported
this information. This has implications for the representativeness
of these samples due to possible selection bias.
EQ-5D
Seven studies examined the convergent validity of the EQ-5D
[20,30,31,35,38,41,47] and one study examined the construct valid-
ity of the EQ-5D by the known groups method [41] (Table 1). Four
studies investigated the responsiveness of the EQ-5D [20,40,41,49].
Seven studies investigating the EQ-5D used population prefer-
Table 2 – Summary of evidence for SF-36 by property
(more detailed evidence is presented in the Appendix
found at doi:10.1016/j.jval.2011.04.006).
Number of studies  ? X
Known groups validity 11 1 0
Convergent validity 7 2 5
Responsiveness 1 2 5
KEY
 Evidence suggests property exists (e.g., statistically significant
difference in scores for knowngroups validity ormoderate to strong
correlations for convergent validity).
? Mixed evidence for property.
X Evidence suggests property does not exist (e.g., weak correlations
for convergent validity).ences to generate an index value [20,30,31,38,40,41,49].Known groups validity
Barton et al. [41] demonstrated known groups validity for the
EQ-5D index whose scores differed according to the severity of
disease. Clinically significant differences in EQ-5D index scores
(defined as0.03) were found between individuals defined as “se-
vere” or “less severe” on seven symptoms or functioning mea-
sures, which included the PANSS, Hamilton depression rating
scale, and global assessment of functioning (GAF).
Convergent validity
Symptommeasures. Correlation with the EQ-5D andmeasures of
symptoms or symptom severity such as the PANSS, symptom
checklist-90-revised (SCL-90R), clinical global impression severity
of illness scale (CGI-S), and brief psychiatry rating scale (BPRS)
weremodest or occasionally strong in three studies [20,30,38]. Two
studies, however, found associations with the PANSSmeasures as
nonexistent or mostly weak [41,47]. Moderate to strong associa-
tions between EQ-5D index scores and depression or anxiety
symptom measures were recorded in one study [41].
Functioning and other quality of life measures. Association with
the functioning measure, GAF, was mixed – it was non-existent in
one study [41] and moderate or strong in two studies [30,38]. Sim-
ilar association between the EQ-5D index and the social and occu-
pational functioning assessment scale (SOFAS) was non-existent
in one study [41], and it was moderate with UK and German ver-
sions of the EQ-5D index (0.44 and 0.42, respectively, P 0.001) [30].
he EQ-5D index was moderately to strongly associated with the
ealth of the nation outcome scales (HoNOS) and weakly to mod-
rately correlated with the global assessment of relational func-
ioning (GARF); whereas EQ-5D health state scores were mostly
oderately to strongly associated with these measures) [30].
Most moderate and significant correlations were found be-
ween the EQ-5D descriptive system health states score and the
chizophrenia quality of life questionnaire (S-QoL) [35]. Barton et
l. [41] found no association between the EQ-5D index and another
chizophrenia-specific HRQL measure, the quality-of-life scale
QLS) [41]. Konig et al. [30] found no association between the EQ-5D
index and direct utilities elicited by the time trade off method.
Responsiveness
Responsiveness data were also mixed. Two studies demonstrated
that the EQ-5D VAS and EQ-5D indexwere responsive to change in
patients [41,49]. There was weak evidence to suggest that EQ-5D
index scores were associated with changes25% on the BPRS and
there was little or no association foundwhen changes on the BPRS
were 25% [20]. Furthermore, van de Willige et al. [40] found that
Q-5D index scores did not respond to changes in most symptom
r functioningmeasures, only showing significant (but not always
oderate or strong) correlations with the PANSS positive sub-
cale, auditory hallucinations rating scale (AHRS), and Groningen
ocial disabilities schedule (GSDS) (–0.39, P  0.005). The EQ-5D
imension and VAS scores appeared to perform better than the
Q-5D index in the same study [40].
SF-36
Fourteen studies examined the construct validity of the SF-36 using
convergent validity [8,21,23,28,32,35–37,39,42,44,46–48] and 12 stud-
ies examined the construct validity of the SF-36 using known groups
validity [19,22–25,28,29,32–34,45,46].Nine studies investigated the re-
sponsiveness of the SF-36 [21,26,27,32,34,36,44,48,50]. (See Table 2 for
concise version of SF-36 validity and responsiveness evidence and
Appendix foundatdoi:10.1016/j.jval.2011.04.006 for furtherdetailson
the evidence for the validity and responsiveness of the SF-36.).
Table 3 – SF-12 and SF-6D validity and responsiveness.
Study Patient characteristics Properties measured Source and types of
measures used to test
convergent validity and/
or responsiveness
Details of validity or
responsiveness
SF-12 validity and
responsiveness
Sanderson (2002) [43] Australia DSM-IV psychosis (not defined).
50 participants (male/female
not provided). No mean age
or range reported. Inpatient/
outpatient status not
reported.
Known groups validity Not applicable Linear regression demonstrated
that individuals with
psychosis were significantly
(P  0.001) more likely to
report disability on the SF-12
than individuals with no
mental health disorder. SF-12
scores were around 12 points
lower in individuals with
psychosis.
SF-6D validity and
responsiveness
McCrone (2009) [20] The
Netherlands, Germany, UK,
and Italy
SCAN interview diagnosed
schizophrenia (classification
scheme not specified).
“Chronic high disability
sample” based on number of
years on medication, number
of psychiatric inpatient days
last year, and GAF score.
N409 (245 males and 164
females). Mean age, 41.5 (SD,
11.5); no range reported.
Convergent validity. Responsiveness Clinician-completed
ii) Symptoms BPRS
Moderate correlation (0.314)
with a symptom measure
(BPRS) at baseline. Weak
correlation (0.22) with
changes in symptom
measure after treatment.
Where improvement on BPRS
was at least 25%, SRM was
moderate in size (0.39).
Where deterioration on BPRS
was at least 25% or
improvement on BPRS 25%,
SRM was very small (0.27 and
0.02, respectively).
BPRS, brief psychiatry rating scale; GAF, global assessment of functioning; SF-6D, short form6D (preference-based) generated from items of the SF-36 or SF-12; SF-12, short form12 (shortened SF-36);
SRM, standardized response mean.
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Table 4 – Quality assessment of included studies.
Study details Properties measured Statistical significance
tested for properties
measured
Difference between groups Clinical significance
addressed or discussed
Missing HRQL data
documented *
Auquier (2003) [35] Convergent validity Yes Not applicable Not reported Not reported (for SF-36)
Badia (1999) [49] Responsiveness Not reported Not reported Not reported Not reported
Barton, G (2009)
[41]
Known groups and convergent
validity. Responsiveness
Yes Not reported Yes Partly – numbers presented
for each analysis which
demonstrate some non-
completion, but no detail
on EQ-5D completion.
Bebbington (2009)
[19]
Known groups validity Yes Not reported but demographics
adjusted for in analysis
Not reported Partly – SF-36 domains were
scored if participants
completed 50% of a
domain. Numbers varied
between dimensions.
However, we are not told
how complete each
dimension is.
Bobes (1997) [37] Convergent validity Yes Not applicable Not reported Not reported
Dunayevich (2007)
[50]
Responsiveness Yes Yes Yes Not reported
Folsom (2009) [24] Known groups validity Yes Yes Not reported Not reported
Jarema (2001) [48] Convergent validity Responsiveness Yes Not applicable Not reported Not reported
Kebede (2004) [33] Known groups validity Not reported Not reported Not reported Not reported
Kebede (2005) [34] Known groups and convergent
validity.
Yes Yes Not reported Not reported
Konig (2007) [30] Convergent validity Yes Not applicable Not reported but floor and ceiling
effects are discussed.
Yes
Konig (2009) [31] Convergent validity Yes Not applicable Not reported Partly – states some missing
values for some variables
and such patients are
excluded. Does not state
what EQ-5D values are
missing.
Law (2005) [46] Known groups and convergent validity Yes Yes Not reported Not reported
Lenert (2005) [8] Convergent validity Yes Not applicable Not reported Not reported
McCrone (2009) [20] Convergent validity and
responsiveness
Yes Not applicable Yes Yes
Meijer (2002) [39] Convergent validity Yes Not applicable Not reported Yes
Milliken ( 2007) [44] Convergent validity and
responsiveness
Yes Not reported Not reported Not reported
Nasrallah (2004)
[25]
Known groups validity and
responsiveness
Yes Yes Yes Not reported
Norholm (2007) [45] Known groups validity Not reported but age-matched
sample used to compare
scores
Yes Not reported Not reported
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Table 4 (continued)
Study details Properties measured Statistical significance
tested for properties
measured
Difference between groups Clinical significance
addressed or discussed
Missing HRQL data
documented *
Phillips (2006) [26] Convergent validity and
responsiveness
Yes Yes Not reported Not reported
Prieto (2004) [38] Convergent validity Yes Not reported Not reported but ceiling effects
discussed
Not reported
Pukrop (2003) [32] Known groups and convergent validity
and responsiveness
Yes Yes Not reported Not reported
Pyne (2003) [27] Responsiveness Yes Not applicable Yes Not reported
Reine (2005) [36] Convergent validity and
responsiveness
Yes Not applicable Yes Not reported
Revicki (1999) [21] Convergent validity and
responsiveness
Yes Yes Yes Not reported
Russo (1998) [28] Known groups and convergent validity Yes Not reported Not reported Not reported
Sanderson (2002)
[43]
Known groups validity Not reported Yes Not reported Not reported
Scalone (2008) [47] Convergent validity Yes Not applicable Not reported Not reported
Sciolla (2003) [29] Known groups validity Yes Yes Not reported Not reported
Strakowski (2005)
[22]
Known groups validity Yes Not reported Not reported Not reported
Tunis (1999) [23] Known groups and convergent validity
and responsiveness
Yes Yes Yes Partly – missing SF-36
values were mentioned
by authors but actual
percentages were not
reported.
van de Willige
(2005) [40]
Responsiveness Yes Not applicable Yes Not reported
Wilkinson (2000)
[42]
Convergent validity Yes Not applicable Not reported Not reported
* Actual missing values from instrument NOT lost to follow-up.
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Eleven studies compared SF-36 scoreswith normative values. Nor-
mative values were taken mostly from general population sam-
ples and published figures, although some studies recruited a
sample of “normal participants” to compare SF-36 scores
[24,29,32]. Almost all studies found statistically significant differ-
ences in SF-36 summary (PCS and MCS) and dimension scores
between individuals with schizophrenia and normative values;
this could be up to 80 points in difference on the MCS and its
dimensions and up to 50 points in difference on the PCS and its
dimensions. Two exceptionswere Sciolla et al. [29] andNorholmet
al. [45], where statistically significant differenceswere noted for all
dimensions except bodily pain.
One study investigated the effect of the presence of side effects
on SF-36 scores. Scores were between two and five points lower on
the PCS and MCS for individuals with some side effects (e.g., sub-
jective rigidity or anticholinergic effect) when compared with
those who did not have those side effects; these differences were
statistically significant [19]. This was not the case, however, for all
side effects; for example the MCS and PCS did not differ between
participants presenting with subjective akathisia and weight gain
(among others).
Convergent validity
Symptom measures. Five studies found mostly weak or non-ex-
stent correlations with symptom measures such as the PANSS,
cale for the Assessment of Negative Symptoms (SANS), Extrapy-
amidal Symptom Rating Scale (ESRS), BPRS, and CGI-S
23,32,36,46,47]. There was some evidence of stronger association
ith the PANSS in two studies [44,48] and the BPRS in another
tudy [28]. Correlations with measures of depression such as the
ontgomery-Åsberg depression rating Scale (MADRS) and Calgary
epression scale for schizophrenia (CDSS) were weak in two stud-
es [28,46] and moderate to strong in another study [23].
Functioning and other quality-of-life measures. Correlation with
he GAF was recorded as weak to moderate in one study [39] and
ery strong in another study [44]. The SOFAS was correlated very
tronglywith the SF-36 [44]. Strong and statistically significant (P
.001) correlations were reported with two schizophrenia-specific
RQLmeasures [35,42]. Revicki et al. [21] described very weak cor-
elations between the SF-36 and schizophrenia-specific QLS total
core. Correlations with generic HRQL measures like the World
ealth Organization quality of life instruments (WHOQoL-BREF,
HOQoL-100, and WHOQoL-26) were mostly moderate to very
trong (i.e., 0.3) [37,46].
Responsiveness
Little evidence existed to demonstrate that when changes were
recorded on the PANSS, this correlated with changes on the SF-36,
with the association beingmostly weak and nonsignificant in four
studies [26,27,48,50]. Pyne et al. [27] also found weak correlations
with changes on the CDSS (–0.27, P 0.01) and the extrapyramidal
symptoms rating scale (ESRS) (–0.22, P  0.05).
Responsiveness was also measured with other measures or by
methods other than calculating correlation between change
scores, but similarly this evidence was weak. Effect sizes calcu-
lated for patients judged to have improved or not improved ac-
cording to CGI-S scores were all nonsignificant apart from for so-
cial functioning, which was small in size [36]. Milliken et al. [44]
found higher MCS scores in remitted versus nonremitted partici-
pants, but this was only a trend and not statistically significant (P
 0.063). Revicki et al. [21] reported that the total MCS indicated
statistically significant contributions for changes in the PANSS
positive scale and the MADRS. Although Pukrop et al. [32] foundthat improvement in negative symptoms significantly impacted
the role physical and role emotional dimensions (and also re-
mained significant when controlling for improvement in negative
symptoms), no such interactions remained significant for any di-
mensions when controlling for improvement in positive symp-
toms. However, Kebede et al. [34] found that SANS and Scale for
the Assessment of Positive Symptoms (SAPS) scores were in-
versely related with improvements in physical and social func-
tioning domains and role limitations due to emotional problems.
SF-12
Data were limited to one study containing known groups validity
evidence, and revealed that individuals with psychosis were sig-
nificantly (P  0.001) more likely to report disability on the SF-12
than individuals with no mental health disorder [43] (Table 3).
SF-6D
Data were limited to one study that demonstrated moderate cor-
relation between the SF-6D index and the symptommeasure BPRS
(–0.344, no P value) [20] (Table 3). When changes occurred on the
BPRS, however, changes in the SF-6D were correlated only weakly
(–0.22, no P value) and appeared only able to respond to changes
on the BPRS greater than 25%. Data for the SF-6D scores were
normally distributed, thus there was no evidence for floor or ceil-
ing effects.
Distributional properties of the measures
Only five studies reported distributional properties of the mea-
sures: three for the EQ-5D [20,30,38]; and one study each for the
SF-36 [23] and SF-6D [20]. Scores were found to be normally dis-
tributed for the SF-36 [23] and SF-6D [20]; thus, there was no evi-
dence of floor or ceiling effects. The three studies which report on
the distributional properties of the EQ-5D [20,30,38], however,
found that the EQ-5D index showed a moderate ceiling effect (for
example, Konig et al. reported 21% of respondents achieved the
maximum score) [30]. This ceiling effect could potentially limit the
responsiveness of the measure. In contrast, two of the three stud-
ies found that the EQ-5D VAS was normally distributed [30,38].
Discussion
Thirty-three studies were identified that examined the validity
and/or responsiveness of four generic HRQL measures, although
very limited datawere found for the generic health statusmeasure
SF-12 and the preference-based SF-6D. The studies were under-
taken in a variety of countries, mostly in Europe and North Amer-
ica, illustrating the wide use of such measures internationally.
Themajority of the evidence (25 studies) examined the validity
and responsiveness of the SF-36. Although there appears to be
strong evidence that the SF-36 is able to distinguish between gen-
eral population norms and scores of people with schizophrenia
(known groups validity), the evidence for convergent validity and
responsiveness is less certain. Similar findings existed for the EQ-
5D, with mixed evidence for the properties of convergent validity
and responsiveness. Indeed, when strong associationswere found
between individual EQ-5D health state dimensions (e.g., anxiety/
depression or self-care) and symptom or functioning measures,
this did not necessarily translate into comparable changes in over-
all EQ-5D index scores such as utility values [30,40]. For psychiatric
research, it may be that the physical health domains are overly
stressed andwith less emphasis onmental health, the total EQ-5D
index scores may not be accurately represented [40].
There was some evidence that associations with measures of
depression were comparatively stronger than those with symp-
tom measures of schizophrenia (e.g., PANSS) [23,30,36,41]. This
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detect this component of HRQL or that depression is the only com-
ponent of HRQLwithin schizophrenia that is important within the
context of HRQL measurement. The issue is whether schizophre-
nia has quality-of-life implications not adequately described by
the five dimensions of the EQ-5D.This is an important issue that
needs to be explored further using a range of research methods,
including qualitative interviews with patients.
Types of measures
When testing association betweenmeasures for convergent valid-
ity (or change scores in responsiveness), there are good reasons to
predict that stronger andmore consistent correlationsmight exist
between generic HRQL measures and functioning (e.g., GAF, SO-
FAS) or mental health/schizophrenia-specific HRQL (e.g., QLS)
measures than purely symptom-based measures such as the
PANSS. These types of measures are more likely to measure sim-
ilar concepts to that of generic HRQL measures and due to this
degree of overlap, we could reasonably assume that these mea-
sures would correlate well with generic HRQL measures. By their
very nature, symptommeasures aremeasuring different concepts
to HRQL measures, so it might be reasonable to predict that it is
less likely that a strong correlation might exist. Similarly, one
might expect a greater degree of association between subjective
measures (completed by patients) and generic HRQL measures
than with objective symptom measures (typically completed by
clinicians).
Re-examining the evidence accounting for the type ofmeasure
used to assess convergent validity (symptom vs. functioning or
HRQLmeasures; subjective vs. objective measures), for whichever
the type of measure the evidence for convergent validity remains
uncertain in this population. Ten studies suggested no or uncer-
tain evidence for a correlation between symptom measures and
generic HRQL measures [8,20,23,32,36,41,46–48] whereas four re-
vealed moderate to strong correlations [28,30,41,44]. Functioning
and schizophrenia HRQL measures did not fare much better, with
four studies indicating strong evidence for convergent validity
[35,38,42,44] and four describing uncertain or no evidence of such
a relationship [21,36,39,41]. Of the seven studies that used objec-
tive measures to test an association, four reported a strong evi-
dence for convergent validity [35,37,42,46] and three found no
such evidence [30,31,41].
Thus, it seems there is a wider issue regarding what types of
measuresmight reasonably be expected to correlate strongly with
generic HRQL measures. It is difficult to determine how strongly
correlated in theory generic HRQLmeasures should bewith symp-
tom and/or other measures and there is little guidance on what
constitutes reasonable correlation. Indeed,Walters [15] noted that
some would say it is impossible to prove validity of HRQL instru-
ments because no “gold standard” exists. Although a number of
different concepts or constructs will be the same or similar be-
tween HRQL and other measures, there will of course be some
areas where there is no overlap. Also, as discussed previously,
where health dimensions and changes appear to have been
missed by preference-based HRQL measures, these may not actu-
ally be important to patients or valued by the general population;
thus it cannot be determined as a weakness of the measure. This
needs to be explored in further research.
Strengths and limitations
This review comprehensively identified studies that reported on
the construct validity and responsiveness of four generic HRQL
measures (SF-6D, SF-12, SF-36, and EQ-5D), and then tabulated and
provided a narrative synthesis of the findings. The review has
some limitations, mainly due to compromising on some elements
of the review process due to the large scope of the project. The
search for studies was reasonably comprehensive, but it was lim-ited to key databases and reference list checking of included stud-
ies, and study selection was undertaken by one reviewer. Ideally,
further searching could be undertaken in trial registries, confer-
ence proceedings, and by citation searching to make the search
process fully comprehensive. Study quality assessment has been
pragmatic and focused on the elements that contribute to HRQL
analysis. The populations included in this review were heteroge-
neous in terms of the nature of schizophrenia (e.g., clinical form,
evolution form, medication), but not all studies provided detailed
or uniform information on these characteristics. Such clinical
variables clearly have an impact on HRQL and these factors will
have had an impact upon the results of individual studies. Never-
theless, this review gives an overall picture of the validity and
responsiveness of these fourmeasures in this population and pro-
vides a starting point for future more focused reviews and future
primary research.
Further research
There is very limited evidence of validity or responsiveness for the
SF-12 and SF-6D and, though they are derivatives of the SF-36, they
have a limited item coverage (12 and 11, respectively) andmay not
perform as well. Therefore, further research needs to be directed
toward demonstrating these properties for these instruments.
Research also needs to be directed toward developing robust
methods of demonstrating validity and responsiveness for generic
HRQLmeasures. For known groups validity, the evidence discrim-
inating between healthy and not healthy individuals could be con-
sidered fairly crude; large differences should be obviously appar-
ent between such groups. Therefore, research is required to
demonstrate an instrument that can reflect these differences be-
tween different severities of the disorder. For convergent validity,
this might mean consideration of which measures to choose for
assessment of strength of correlation, both by considering the
type of measure (e.g., symptom functioning or HRQL) and the na-
ture of measure (subjective or objective). Studies need to be ex-
plicit at their outset about the hypothesized associations when
investigating validity and responsiveness. In addition, wherever
studies can investigate feasibility of generic HRQL measures
alongside construct validity and responsiveness within this dis-
ease area, this will allow a greater overall understanding of which
measures are useful within schizophrenia.
This review was limited to examining quantitative evidence,
but researchers and regulatory authorities, such as the Food and
Drug Administration and the European Medicines Agency, also
require qualitative evidence on the validity ofmeasures in specific
patient groups based on interviews with patients [51,52]. Some of
the questions raised in this review might be better addressed
through the use of qualitative interviews with patients who will
provide greater insight into the shortcomings of these generic
measures. Whereas qualitative research indicates generic mea-
sures, such as the EQ-5D and SF-6D, are not suitablewithin schizo-
phrenia, alternative HRQL measures need to be found. One alter-
native is to develop a preference-basedmental health index based
on either an existing measure or the development of a new one
[53]. Another alternative would be to develop “add-on” dimen-
sions that reflect the concerns of patients withmental health con-
ditions like schizophrenia.
Conclusion
In conclusion, the evidence found in this review on the validity and
responsiveness for a number of widely used generic measures in
patients with schizophrenia has beenmixed. Although the evidence
base is limited in a number of important respects (including prob-
lemswith themeasures used to develop constructs in the validation
studies), it is sufficient to raise doubts about the use of generic mea-
([
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
919V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 0 7 – 9 2 0sures of health like the EQ-5D and SF-36 in patientswith schizophre-
nia. This suggests that agencies, such as NICE, which advise on re-
imbursement of health costs, should be willing to consider evidence
on health state utility values based on other methods.
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